At the news
? BEARISHIMPACT 7/10 8-K filed Apr 7, 2026 at 06:58 ET
Soleno Therapeutics has voluntarily withdrawn its marketing authorization application (MAA) for VIOKAT (VYKATTM XR) in Europe for Prader-Willi syndrome, citing business and strategic considerations. The decision preserves the option to re-engage with regulators in the future, but removes near-term commercial prospects in Europe.
- Soleno Therapeutics withdrew its MAA for VIOKAT (diazoxide choline) in Europe for Prader-Willi syndrome (PWS).
- The application was under review by the European Medicines Agency (EMA) with a decision expected in mid-2026.
- The withdrawal was voluntary and based on 'business and strategic considerations'.
- The company retains the ability to re-engage with regulators in the future if a viable pathway emerges.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access